Skip to main content
Log in

Long term effects of vincristine on the peripheral nervous system

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

Forty patients with Non-Hodgkin's Lymphoma treated with vincristine between 1984 and 1990 (cumulative dose 12 mg in 18–24 weeks) were investigated in order to evaluate the long term effects of vincristine on the peripheral nervous system. The patients were interviewed with emphasis on neuropathic symptoms. Physical and quantitative sensory examination with determination of vibratory perception and thermal discrimination thresholds were performed, four to 77 months (median 34 months) after vincristine treatment. Twenty-seven patients reported neuropathic symptoms. In 13 of these 27 patients symptoms were still present at the time of examination. In these patients sensory signs and symptoms predominated. In the other 14 patients symptoms had been present in the past. Symptoms persisted maximally 40 months since cessation of therapy. There was no age difference between patients with and without complaints at the time of examination. Normal reflexes were found in two third of patients. Neuropathic complaints were not very troublesome on the long term. It is concluded that with the above mentioned vincristine dose schedule signs and symptoms of vincristine neuropathy are reversible for a great deal and prognosis is fairly good.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Carbone PP, Bono V, Frei E, III, Brindley CO: Clinical studies with vincristine. Blood 21: 640–647, 1963

    PubMed  Google Scholar 

  2. Rosenthal S, Kaufman S: Vincristine neurotoxicity. Ann Intern Med 80: 733–737, 1974

    PubMed  Google Scholar 

  3. Weiss HD, Walker MD, Wiernik PH: Neurotoxicity of commonly used antineoplastic agents. N Engl J Med 291: 127–133, 1974

    PubMed  Google Scholar 

  4. Holland JF, Scharlau C, Gailani S, Krant MJ, Olson KB, Horton J, Shnider BI, Lynch JJ, Owens A, Carbone PP, Colsky J, Grob D, Miller SP, Hall TC: Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Res 33: 1258–1264, 1973

    PubMed  Google Scholar 

  5. Casey EB, Jellife AM, Le Quesne PM, Millett YL: Vincristine neuropathy. Brain 96: 69–86, 1973

    PubMed  Google Scholar 

  6. Sandler SG, Tobin W, Henderson ES: Vincristine-induced neuropathy. Neurology 19: 367–374, 1969

    PubMed  Google Scholar 

  7. Legha SS: Vincristine neurotoxicity. Med Toxicol 1: 421–427, 1986

    PubMed  Google Scholar 

  8. Sahenk Z, Brady ST, Mendell JR: Studies on the pathogenesis of vincristine-induced neuropathy. Muscle Nerve 10: 80–84, 1987

    PubMed  Google Scholar 

  9. Gottschalk PG, Dyck PJ, Kiely JM: Vinca alkaloid neuropathy: nerve biopsy studies in rats and in man. Neurology 18: 875–882, 1968

    PubMed  Google Scholar 

  10. Rosenberg RF, Caridi JG: Vincristine-induced megacolon. Gastrointest Radiol 8: 71–73, 1983

    PubMed  Google Scholar 

  11. Hirvonen HE, Salmi TT, Heinonen E, Atilla KJ, Välimäki IAT: Vincristine treatment of acute lymphoblastic leukemia induces transient autonomic cardioneuropathy. Cancer 64: 801–805, 1989

    PubMed  Google Scholar 

  12. Hancock BW, Naysmith A: Vincristine-induced autonomic neuropathy. Br Med J 3: 207, 1975

    Google Scholar 

  13. Shurin SB, Rekate HL, Annable W: Optic atrophy induced by vincristine. Pediatrics 70: 288–291, 1982

    PubMed  Google Scholar 

  14. Teichmann KD, Dabbagh N: Severe visual loss after a single dose of vincristine in a patient with spinal cord astrocytoma. J Ocul Pharmacol 4: 117–121, 1988

    PubMed  Google Scholar 

  15. Delaney P: Vincristine-induced laryngeal nerve paralysis. Neurology 32: 1285–1288, 1982

    PubMed  Google Scholar 

  16. Lugassy G, Shapira A: Sensorineural hearing loss associated with vincristine treatment. Blut 61: 320–321, 1990

    PubMed  Google Scholar 

  17. Jackson DV, Sethi VS, Spurr CL, McWhorter JM: Pharmacokinetics of vincristine in the cerebrospinal fluid of humans. Cancer Res 41: 1466–1468, 1981

    PubMed  Google Scholar 

  18. Goldberg JM, Lindblom U: Standardised method of determining vibratory perception thresholds for diagnosis and screening in neurological investigation. J Neurol Neurosurg Psychiatry 42: 793–803, 1979

    PubMed  Google Scholar 

  19. Bertelsmann FW, Heimans JJ, Weber EJM, Van der Veen EA, Schouten JA: Thermal discrimination thresholds in normal subjects and in patients with diabetic neuropathy. J Neurol Neurosurg Psychiatry 48: 686–690, 1985

    PubMed  Google Scholar 

  20. McLeod JG, Penny R: Vincristine neuropathy: an electrophysiological and histological study. J Neurol Neurosurg Psychiatry 32: 297–304, 1969

    PubMed  Google Scholar 

  21. Bradley WG, Lassman LP, Pearce GW, Walton JN: The neuromyopathy of vincristine in man. J Neurol Sci 10:107–131, 1970

    PubMed  Google Scholar 

  22. Benoit P, Destee A, Warot P: Neuropathie motrice étendue après une dose unique de vincristine. Therapie 41: 517–520, 1986

    Google Scholar 

  23. Maeda K, Ueda M, Ohtaka H, Koyama Y, Ohgami M, Miyazaki H: A massive dose of vincristine. Jpn J Clin Oncol 17: 247–253, 1987

    PubMed  Google Scholar 

  24. Hildebrand J, Coers C: Etude clinique, histologique et electrophysiologique des neuropathies associees au traitement par la vincristine. Eur J Cancer 1: 51–58, 1965.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Postma, T.J., Benard, B.A., Huijgens, P.C. et al. Long term effects of vincristine on the peripheral nervous system. J Neuro-Oncol 15, 23–27 (1993). https://doi.org/10.1007/BF01050259

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01050259

Key words

Navigation